These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35802461)

  • 1. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.
    Little JS; Aleissa MM; Beluch K; Gonzalez-Bocco IH; Marty FM; Manne-Goehler J; Koo S; Hammond SP; Jacobson CA
    Blood Adv; 2022 Aug; 6(16):4821-4830. PubMed ID: 35802461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy.
    Goldsmith SR; Shouse G; Wong FL; Bosworth A; Iukuridze A; Chen S; Rhee JW; Mei M; Htut M; Janakiram M; Forman SJ; Pillai R; Budde LE; Armenian SH
    Transplant Cell Ther; 2024 Sep; 30(9):927.e1-927.e9. PubMed ID: 38871057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis.
    Pennese E; Salutari P; Carriero L; Restuccia F; De Filippis AF; De Luca G; Giancola R; Guardalupi F; Corradi G; Fabi B; Baldoni S; Di Ianni M
    Front Immunol; 2023; 14():1272798. PubMed ID: 37841271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
    Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recapitulated Late-Onset Inflammatory Toxicities and Progressive Dysautonomia with Persistence of Central Memory CD4+ Chimeric Antigen Receptor T Cells in a Case of Transformed Follicular Lymphoma: Case Report.
    Nishimoto M; Takakuwa T; Kuno M; Makuuchi Y; Okamura H; Nakashima Y; Koh H; Namba H; Itoh Y; Hino M; Nakamae H
    Acta Haematol; 2023; 146(4):338-342. PubMed ID: 37088083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
    Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
    Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis.
    Pernas B; Iacoboni G; Los-Arcos I; Carpio C; Márquez-Algaba E; Sanchez-Salinas MA; Albasanz A; Esperalba J; Viñado B; Camps IR; Barba P
    Eur J Haematol; 2024 Aug; 113(2):227-234. PubMed ID: 38665060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
    Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties.
    Haidar G; Garner W; Hill JA
    Curr Opin Infect Dis; 2020 Dec; 33(6):449-457. PubMed ID: 33009139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
    Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
    Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive Fungal Disease Among Pediatric and Adolescent Patients Undergoing Itraconazole Prophylaxis After Hematopoietic Stem Cell Transplantation.
    Itsaradisaikul S; Pakakasama S; Boonsathorn S; Techasaensiri C; Rattanasiri S; Apiwattanakul N
    Transplant Proc; 2021; 53(6):2021-2028. PubMed ID: 33994183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential low-dose CT thorax scans to determine invasive pulmonary fungal infection incidence after allogeneic hematopoietic cell transplantation.
    Enger K; Tonnar X; Kotter E; Bertz H
    Ann Hematol; 2023 Feb; 102(2):413-420. PubMed ID: 36460795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study.
    Wang J; Alkrekshi A; Dasari S; Lin HC; Elantably D; Armashi ARA
    Bone Marrow Transplant; 2023 Nov; 58(11):1223-1228. PubMed ID: 37604871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center.
    Lum L; Lee A; Vu M; Strasser S; Davis R
    Transpl Infect Dis; 2020 Dec; 22(6):e13361. PubMed ID: 32510755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study.
    Ye P; Pei R; Hu Y; Chen D; Li S; Cao J; Li F; Wu M; Fang Y; Lu Y
    BMC Infect Dis; 2022 May; 22(1):465. PubMed ID: 35570276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
    Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
    Front Immunol; 2022; 13():879983. PubMed ID: 35669773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: Impact of national programme of antifungal prophylaxis.
    Czyżewski K; Gałązka P; Frączkiewicz J; Salamonowicz M; Szmydki-Baran A; Zając-Spychała O; Gryniewicz-Kwiatkowska O; Zalas-Więcek P; Chełmecka-Wiktorczyk L; Irga-Jaworska N; Bień E; Ociepa T; Wawryków P; Tomaszewska R; Płonowski M; Pierlejewski F; Gamrot-Pyka Z; Małas Z; Urbanek-Dądela A; Stolpa W; Zaucha-Prażmo A; Goździk J; Chaber R; Gil L; Styczyński J
    Mycoses; 2019 Nov; 62(11):990-998. PubMed ID: 31429997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
    Juluri KR; Wu QV; Voutsinas J; Hou J; Hirayama AV; Mullane E; Miles N; Maloney DG; Turtle CJ; Bar M; Gauthier J
    Blood Adv; 2022 Apr; 6(7):2055-2068. PubMed ID: 34666344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.